Evaluation of myeloid-derived suppressor cells (MDSC), a cell type implicated in T-cell suppression, may inform immune status. However, a uniform methodology is necessary for prospective testing as a biomarker.
Introduction
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of granulocyte-and monocyte-like cells that inhibit T-cell function (1, 2) . Clinically significant MDSC accumulation has been observed in many challenges to the immune system in humans including chronic infection, transplant and multiple malignancies (3) (4) (5) (6) (7) (8) (9) (10) cancer, melanoma, and others), chronic infection (HIV), cirrhosis, and allotransplantation (5, 8, (11) (12) (13) (14) (15) (16) (17) .
In melanoma, m-MDSCs correlate with melanoma disease activity and are independently prognostic of overall survival in patients with stage IV disease (6, (18) (19) (20) .
Levels of m-MDSC inversely correlate with the presence of NY-ESO-1-specific T cells and appear to be increased in ipilimumab non-responders (20, 21) . This suggests a link between m-MDSC and antigen-specific immunity in vivo and provides additional rationale for routinely evaluating m-MDSCs as a biomarker in the context of immunotherapy clinical trials. However, a uniform methodology that corrects for artifacts introduced by cell processing, cryopreservation, and analysis needs to be developed to enable routine measurement of m-MDSC for prospective testing as a biomarker (22) .
Immunomodulatory therapy, which has emerged as a promising treatment approach for metastatic melanoma and other cancers, is an area where biomarker development may enable selection of therapy for individuals more likely to achieve prolonged overall survival.
Ipilimumab, an antibody that blocks the function of the immune inhibitory molecule cytotoxic T lymphocyte antigen 4 (CTLA-4), was the first immunomodulatory antibody to gain regulatory approval as a cancer therapeutic based on two phase III studies demonstrating significant increases in overall survival (OS) in patients with metastatic melanoma (23, 24) . However, only 20-30% of patients achieve long-term survival following therapy (25) . This not only supports the need to define biomarkers in this context, but also to identify mechanisms of resistance that could lead to additional therapeutic targets for improved outcomes.
A number of biomarkers examining T-cell proliferation or activation, and antigen-specific immunity have been assessed in the context of ipilimumab therapy. Gene expression profiling on tumor biopsies collected from 45 melanoma patients before and after ipilimumab treatment showed that an immunologically active tumor microenvironment favors clinical response to ipilimumab (26, 27 We report the development of methods to enable uniform analysis of m-MDSC that overcomes issues related to blood processing and inter-user variability. This is achieved by deriving a measure of m-MDSC using coefficient of variance (CV) to assess HLA-DR spread on CD14 + /CD11b + cells and through the evaluation of stabilizers of HLA-DR levels in whole blood. We validate these methods by demonstrating that CD14 + /HLA-DR low/-m-MDSC quantity derived from CV values are both inversely correlated with pharmacodynamics markers of ipilimumab function and also associated with overall survival among patients undergoing treatment with ipilimumab.
MATERIALS AND METHODS

Patients
We with four doses of ipilimumab 10 mg/kg or 3mg/kg IV every 3 weeks during induction therapy, followed by maintenance ipilimumab at the same dose every 12 weeks, starting at week 24.
Clinical benefit was determined by investigators at week 24 imaging based upon interpretation Absolute number of m-MDSC (/μL) in peripheral blood was estimated using the formula;
(%m-MDSC) x (number of monocytes (/ L) from a complete blood count on the same day.
T-cell suppression assay
A T-cell suppression assay was performed as described previously (32) . Briefly, CD14 
Statistics
Patient characteristics were described using median and range for continuous variables and frequency and percentages for categorical variables. The primary endpoint for this retrospective analysis was overall survival, which is defined as the time from pre-treatment %m-MDSC assessment to death or last follow-up. Landmark analysis from week 6 was also performed.
Patients alive at last follow-up are censored. Maximally selected log-rank statistics was used to find a cutoff value for %m-MDSC. The Kaplan-Meier method and log-rank test were used to compare differences in survival for categorical variables. Univariate and multivariate Cox proportional hazards regression was used to assess the association between clinical variables and overall survival. A student's T test with Welch's correction was used for comparisons of %m-MDSC frequency in patient and healthy donor groups. Pearson correlation was used to evaluate for relationships between %m-MDSC and lymphocyte subsets.
Results
Measuring HLA-DR spread using a computational algorithm removes user bias and inter-replicate variability in m-MDSC assessment.
on October Given the potential for changes in HLA-DR expression that may occur during blood processing or transport to significantly alter m-MDSC evaluation we evaluated our methods in whole blood stored at room temperature as well as cryopreserved ficoll purified PBMCs. We noted CV HLA-DR was significantly reduced as the interval between phlebotomy time and analysis increased: a 48h delay until processing demonstrated a nearly 50% reduction from baseline.
Levels of CV HLA-DR were however consistent over time in cyto-chex® blood collection tubes even if whole blood was stored at room temperature prior to processing for up to 8 
than in healthy donor controls.
Using our CV HLA-DR /%m-MDSC conversion nomogram, we determined the relative frequency of m-MDSC for 68 melanoma patients treated with ipilimumab at either 10mg/kg (n= 28) or 3mg/kg (n= 40) for whom pre-treatment and week 6 PBMC samples were processed the same day as phlebotomy and stored in our tissue repository. We again used healthy donors as controls. The baseline characteristics of the patients and healthy donors are described in Table   1 . Overall median time from initial m-MDSC measurement to last recorded follow-up was 13.6 months (range 0.66-63.9).
We found that the relative frequency of peripheral blood m-MDSC was increased In order to evaluate the hypothesis that lower frequency of m-MDSC was associated with overall survival, we parsed our patients according to their %m-MDSC at baseline and after 2 doses of ipilimumab (week 6). Based on logrank statistics within our ipilimumab-treated cohort we defined 14.9% as the cutoff between "high" and "low" %m-MDSC. The distribution 
of m-MDSC frequencies among analyzed patients is summarized in Table 1 .
Having less than 14.9% m-MDSC pre-treatment was associated with improved OS among 68 patients treated with ipilimumab ( Figure 2C, Table 2 ) with a HR of 0.35 (95%CI: 0.18 -0.70, p=0.003). When analyzed by individual dose groups, the difference was seen in patients treated at 10 mg/kg, but not at 3 mg/kg (Table S1 ). We performed univariate (Table 2) and multivariate analysis (Table 3 ) to evaluate the impact of ALC, LDH, and monocyte counts on survival in our patient cohort. %m-MDSC < 14.9% correlated with superior OS on both univariate and multivariate analysis.
Monocyte quantity was not predictive suggesting %m-MDSC represents a relative activation state within the monocyte compartment and is not a direct reflection of monocyte numbers.
On Treatment (week 6), the frequency of m-MDSC correlates with overall survival (OS) in patients treated with ipilimumab.
We also evaluated associations between %m-MDSC at week 6 and OS similarly to what has been evaluated previously for ALC ( Table 2, Table S1 ) (30, 34) . %m-MDSC below 14.9% at week 6 was associated with superior OS (Figure 2D ) in patients receiving ipilimumab treatment with a HR of 0.38 (95%CI: 0.19 -0.75, p=0.005). As expected ALC greater than or equal to 1000 at week 6 was associated with improved OS in our cohort and normal LDH (<250) at week 6 correlated with improved OS in patients treated with ipilimumab. To address potential confounding by ALC and LDH, a multivariate analysis was performed and week 6 %m-MDSC remained significantly associated with OS, even when accounting for both LDH and week 6 ALC. (Table 3) .
%m-MDSC is inversely correlated with CD8 + T-cell rise on therapy and suppresses T-cell proliferation in vitro.
Ipilimumab has a specific pharmacodynamic effect on absolute lymphocyte counts, but data on the specific subset of cells affected is limited. Our group previously reported on 35 
Discussion
We developed an objective methodology to evaluate m-MDSC frequency in the peripheral blood of metastatic melanoma patients receiving immunotherapy with ipilimumab at our center. In our single institution cohort, we found that patients with metastatic melanoma have a greater frequency of m-MDSC than a group of healthy donors. An m-MDSC quantity prior to treatment and at week 6 that was outside the healthy donor range that we defined was significantly associated with inferior overall survival, independent of LDH (at baseline and week 6) and ALC (at week 6) in a multivariate model. Our observations suggest that m-MDSC frequency is a novel prognostic indicator of overall survival in metastatic melanoma patients treated with ipilimumab.
The CV-based cutoff presented here represents an objective methodology for determining m-MDSC composition independent of fluorescence variability in FACS analysis.
The cutoff level derived here was consistent with a level greater than the 99%ile of a preliminary cohort of healthy donor m-MDSC, suggesting that our method enables distinction of normal versus abnormal CV HLA-DR and m-MDSC evaluation in a prospective fashion. Thus, we suggest that using healthy donors as a calibration can lead to an easily implementable, automated and objective tool for monitoring the frequency of m-MDSC within patients' blood samples, and distinguish between "normal" and "high" ranges.
However, it is important to note the preliminary nature of our healthy donor range and that further study of the effects of age, gender, BMI, and non-malignant comorbid conditions on CV HLA-DR are necessary to propose a "cutoff" value capable of prospectively segregating melanoma patients more or less likely to benefit from ipilimumab.
As the coefficient of variation (CV) is defined as the ratio of the standard deviation to the mean, we obtained a metric independent of non-biologically meaningful fluctuations in sample handling, FACS protocol and fluorescence intensity. While using "non-normalized" were associated with greater suppressive activity. We propose that in melanoma patients receiving ipilimumab, the pharmacodynamic effects on lymphocyte subset increase and the 
quantity of m-MDSC are interrelated and worthy of further study as pharmacodynamic markers of therapeutic efficacy perhaps sufficient to guide risk-adapted clinical trial design.
Furthermore, taken together the observations reported here suggest the hypothesis that m-MDSC suppression of lymphocytes may be limiting the therapeutic benefit of ipilimumab.
A larger cohort of patients will need to be studied to confirm our findings and to assess if escalating ipilimumab dose or combination therapies including m-MDSC-directed therapies can modulate CD8
+ and m-MDSC interactions.
In our study we developed an objective method to evaluate pre-treatment (27) 10 ( 
